Latest news
Alnylam Pharmaceuticals Share Price Weakness Looks 'Overdone' Despite Softer Quarter, RBC Says - Yahoo FinanceYahoo Finance · Fri, 31 Jul 2026 07:00:00 GMTRBC Thinks Alnylam’s Post-Earnings Dip Looks Overdone - FinimizeFinimize · Fri, 31 Jul 2026 07:00:00 GMTRBC Cuts Price Target on Alnylam Pharmaceuticals to $350 From $445, Keeps Outperform Rating - Yahoo FinanceYahoo Finance · Fri, 31 Jul 2026 07:00:00 GMT